23:54 , May 8, 2019 |  BC Extra  |  Company News

May 8 Company Quick Takes: Takeda selling Shire eye drug to Novartis in $3.4B deal; plus BioNTech, Third Rock’s Thrive and more

Takeda off-loads Xiidra, TachoSil  Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) will sell Xiidra lifitegrast to Novartis AG (NYSE:NVS; SIX:NOVN) for $3.4 billion up front, plus $1.9 billion in milestones. Takeda said divesting the dry eye...
21:15 , Mar 5, 2019 |  BC Innovations  |  Distillery Techniques

Vascularized kidney organoids for modeling renal disease

TECHNIQUES CATEGORY: Disease models TECHNOLOGY: 3-D models Vascularized kidney organoids could be used to study kidney development and model renal diseases. The organoids are generated in three steps: culturing human pluripotent stem cells with fibroblast...
00:06 , Jan 23, 2019 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles; polymers A fibrin gel-nanoparticle system could be used to deliver anti-CD47 antibodies to treat cancer. The system consists of a fibrin-based polymer gel containing fibrinogen, thrombin and calcium carbonate nanoparticles that is loaded...
20:50 , Dec 19, 2018 |  BC Innovations  |  Distillery Therapeutics

Hematology

INDICATION: Bleeding In vitro and human plasma studies identified a peptide-based plasmin inhibitor that could help treat bleeding. Chemical synthesis and in vitro testing of analogs of a sunflower cyclic peptide serine protease inhibitor in...
23:52 , Dec 11, 2018 |  BC Extra  |  Preclinical News

Anti-CD47 gel prevents cancer recurrence after surgery

ZenCapsule Inc. (Los Angeles, Calif.) is developing a localized sprayable gel similar to an anti-CD47 immunotherapeutic gel described in a new paper from University of California Los Angeles researchers that prevented postsurgical cancer recurrence in...
21:21 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Vertex discontinues development of spinal cord injury compound VX-210

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) discontinued development of acute spinal cord injury candidate VX-210 after a DSMB recommended stopping a Phase IIb trial for futility following an interim analysis. Vertex has rights to VX-210 from BioAxone...
17:58 , Oct 25, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease; neurology

INDICATION: Multiple sclerosis (MS); Alzheimer’s disease (AD) Mouse studies suggest a mAb against fibrin could help treat MS and AD. In a mouse model of chronic MS and two mouse models of relapsing-remitting MS (RRMS),...
21:19 , Oct 15, 2018 |  BC Extra  |  Preclinical News

mAb blocks fibrin's inflammation without clotting interference to treat MS, Alzheimer's

Gladstone Institutes researchers developed a mAb that could help treat neurodegenerative and autoimmune CNS diseases such as multiple sclerosis or Alzheimer's disease by specifically blocking the proinflammatory effects of fibrin without compromising its clotting ability....
19:27 , Sep 10, 2018 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles Nanoparticles bound to red blood cells (RBCs) could be used to deliver drugs to the vasculature of specific organs. The method involves mixing bare nanogels with ex vivo RBCs to enable RBC-nanoparticle binding,...
23:05 , Aug 1, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: July 2018

New Therapeutic Targets and Biomarkers: July 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during July 2018. Therapeutic targets are defined as any protein, gene or other...